Klein, Klara R.
Buse, John B. http://orcid.org/0000-0002-9723-3876
Article History
First Online: 12 May 2022
Competing interests
: K.R.K. and J.B.B. have worked with vTv Therapeutics, the developers of the GKA TTP-399, as investigators and collaborators without direct financial benefit. J.B.B. has provided consultation to Novo Nordisk, with fees paid to the University of North Carolina; has grant support from Dexcom, NovaTarg, Novo Nordisk, Sanofi, Tolerion and vTv Therapeutics; is a consultant with personal compensation from Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Boehringer-Ingelheim, CeQur, Cirius Therapeutics Inc., Dasman Diabetes Center (Kuwait), Eli Lilly, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, Mediflix, Medscape, Mellitus Health, Pendulum Therapeutics, Praetego, Stability Health, Valo and Zealand Pharma; and has received stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego and Stability Health.